Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:TMEM106B-ABCB5

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: TMEM106B-ABCB5
	FusionPDB ID: 91512
	FusionGDB2.0 ID: 91512
		Hgene	Tgene
	Gene symbol	TMEM106B	ABCB5
	Gene ID	54664	340273
	Gene name	transmembrane protein 106B	ATP binding cassette subfamily B member 5
	Synonyms	HLD16	ABCB5alpha\|ABCB5beta\|EST422562
	Cytomap	7p21.3	7p21.1
	Type of gene	protein-coding	protein-coding
	Description	transmembrane protein 106B	ATP-binding cassette sub-family B member 5ABCB5 P-gpATP-binding cassette proteinATP-binding cassette, sub-family B (MDR/TAP), member 5P-glycoprotein ABCB5
	Modification date	20200313	20200313
	UniProtAcc	.	Q2M3G0 Main function of 5'-partner protein: FUNCTION: Energy-dependent efflux transporter responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:12960149, PubMed:22306008, PubMed:15899824, PubMed:15205344). Specifically present in limbal stem cells, where it plays a key role in corneal development and repair (By similarity). {ECO:0000250\|UniProtKB:B5X0E4, ECO:0000269\|PubMed:12960149, ECO:0000269\|PubMed:15205344, ECO:0000269\|PubMed:15899824, ECO:0000269\|PubMed:22306008}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000396667, ENST00000396668, ENST00000453686,	ENST00000406935, ENST00000443026, ENST00000477094, ENST00000258738, ENST00000404938,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	6 X 6 X 4=144	8 X 7 X 5=280
	# samples	6	8
	** MAII score	log2(6/144*10)=-1.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(8/280*10)=-1.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: TMEM106B [Title/Abstract] AND ABCB5 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: TMEM106B [Title/Abstract] AND ABCB5 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	TMEM106B(12258147)-ABCB5(20778606), # samples:1
Anticipated loss of major functional domain due to fusion event.	TMEM106B-ABCB5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TMEM106B-ABCB5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TMEM106B-ABCB5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. TMEM106B-ABCB5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	ABCB5	GO:0042391	regulation of membrane potential	12960149
Tgene	ABCB5	GO:0055085	transmembrane transport	12960149

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:12258147/chr7:20778606)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across TMEM106B (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ABCB5 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000396668

TMEM106B

chr7

12258147

ENST00000404938

ABCB5

chr7

20778606

2760

468

109

1374

421

ENST00000396668

TMEM106B

chr7

12258147

ENST00000258738

ABCB5

chr7

20778606

1375

468

109

1374

422

ENST00000396667

TMEM106B

chr7

12258147

ENST00000404938

ABCB5

chr7

20778606

2895

603

322

1509

395

ENST00000396667

TMEM106B

chr7

12258147

ENST00000258738

ABCB5

chr7

20778606

1510

603

322

1509

396

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000396668	ENST00000404938	TMEM106B	chr7	12258147	+	ABCB5	chr7	20778606	+	0.000456764	0.9995433
ENST00000396668	ENST00000258738	TMEM106B	chr7	12258147	+	ABCB5	chr7	20778606	+	0.002127179	0.9978728
ENST00000396667	ENST00000404938	TMEM106B	chr7	12258147	+	ABCB5	chr7	20778606	+	0.000466325	0.99953365
ENST00000396667	ENST00000258738	TMEM106B	chr7	12258147	+	ABCB5	chr7	20778606	+	0.001985553	0.99801445

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TMEM106B-ABCB5

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
TMEM106B	chr7	12258147	ABCB5	chr7	20778606	468	115	QLVALIPYSDQRLRPRRTVFTAIAYG
TMEM106B	chr7	12258147	ABCB5	chr7	20778606	603	89	QLVALIPYSDQRLRPRRTVFTAIAYG

Top

Potential FusionNeoAntigen Information of TMEM106B-ABCB5 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

TMEM106B-ABCB5_12258147_20778606.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:01	RLRPRRTVF	0.9886	0.906	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B14:02	QRLRPRRTV	0.9847	0.7818	10	19
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B14:01	QRLRPRRTV	0.9847	0.7818	10	19
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-A30:08	RLRPRRTVF	0.8606	0.7166	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:25	RLRPRRTVF	0.8501	0.9121	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B08:09	DQRLRPRRT	0.6956	0.5148	9	18
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-A32:13	RLRPRRTVF	0.6769	0.8396	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:03	RLRPRRTVF	0.6687	0.7757	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-A74:11	ALIPYSDQRLR	0.9914	0.8787	3	14
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-A74:03	ALIPYSDQRLR	0.9914	0.8787	3	14
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-A74:09	ALIPYSDQRLR	0.9914	0.8787	3	14
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-A31:06	ALIPYSDQRLR	0.9882	0.8097	3	14
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B73:01	QRLRPRRTV	0.9843	0.7478	10	19
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-C07:05	QRLRPRRTV	0.9766	0.9487	10	19
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:07	RLRPRRTVF	0.9722	0.7406	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:04	RLRPRRTVF	0.9659	0.9144	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B27:03	QRLRPRRTVF	0.997	0.5533	10	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B27:10	QRLRPRRTV	0.9994	0.5351	10	19
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:135	RLRPRRTVF	0.9898	0.9078	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:27	RLRPRRTVF	0.9886	0.9254	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:33	RLRPRRTVF	0.9886	0.906	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:34	RLRPRRTVF	0.9886	0.906	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:125	RLRPRRTVF	0.9886	0.906	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:24	RLRPRRTVF	0.9859	0.8901	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-C06:08	QRLRPRRTV	0.965	0.9871	10	19
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:50	RLRPRRTVF	0.9638	0.8557	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:35	RLRPRRTVF	0.9607	0.9161	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-A32:01	RLRPRRTVF	0.9267	0.8795	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:12	RLRPRRTVF	0.9211	0.861	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-C07:01	QRLRPRRTV	0.9177	0.6683	10	19
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:53	RLRPRRTVF	0.9043	0.898	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:68	RLRPRRTVF	0.8969	0.6663	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-A30:01	RLRPRRTVF	0.8849	0.8419	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:54	RLRPRRTVF	0.8676	0.8812	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:39	RLRPRRTVF	0.8466	0.8321	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:73	RLRPRRTVF	0.6955	0.7701	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B58:06	RLRPRRTVF	0.5787	0.7203	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B15:30	RLRPRRTVF	0.4405	0.8742	11	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-C06:02	QRLRPRRTV	0.2126	0.9908	10	19
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-C06:17	QRLRPRRTV	0.2126	0.9908	10	19
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-B27:10	QRLRPRRTVF	0.9998	0.6098	10	20
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	HLA-A74:01	ALIPYSDQRLR	0.9914	0.8787	3	14

Top

Potential FusionNeoAntigen Information of TMEM106B-ABCB5 in HLA II

TMEM106B-ABCB5_12258147_20778606.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1457	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1501	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1501	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1501	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1502	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1502	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1502	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1503	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1503	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1503	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1504	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1504	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1504	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1505	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1505	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1505	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1506	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1506	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1506	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1507	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1507	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1507	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1508	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1508	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1508	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1509	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1509	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1509	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1510	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1510	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1510	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1511	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1511	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1511	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1512	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1512	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1512	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1513	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1513	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1513	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1514	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1514	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1514	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1515	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1515	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1515	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1516	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1516	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1516	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1518	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1518	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1518	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1519	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1519	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1519	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1520	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1520	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1520	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1521	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1521	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1521	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1522	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1522	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1522	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1523	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1523	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1523	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1524	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1524	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1524	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1525	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1525	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1525	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1526	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1526	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1526	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1527	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1528	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1528	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1528	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1529	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1529	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1529	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1530	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1530	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1530	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1531	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1531	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1531	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1532	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1532	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1532	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1533	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1533	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1533	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1535	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1535	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1535	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1535	ALIPYSDQRLRPRRT	3	18
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1536	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1536	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1536	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1537	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1537	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1537	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1538	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1538	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1538	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1539	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1539	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1539	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1540	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1540	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1540	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1541	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1541	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1541	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1542	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1542	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1542	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1543	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1543	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1543	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1544	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1544	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1544	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1545	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1545	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1545	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1546	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1546	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1546	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1547	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1547	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1547	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1548	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1548	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1548	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1549	LVALIPYSDQRLRPR	1	16
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1549	VALIPYSDQRLRPRR	2	17
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1549	QLVALIPYSDQRLRP	0	15
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	603	DRB1-1615	LVALIPYSDQRLRPR	1	16

Top

Fusion breakpoint peptide structures of TMEM106B-ABCB5

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
7118	PYSDQRLRPRRTVF	TMEM106B	ABCB5	chr7	12258147	chr7	20778606	603

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TMEM106B-ABCB5

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	7118	PYSDQRLRPRRTVF	-7.9962	-8.1096
HLA-B14:02	3BVN	7118	PYSDQRLRPRRTVF	-5.70842	-6.74372
HLA-B52:01	3W39	7118	PYSDQRLRPRRTVF	-6.83737	-6.95077
HLA-B52:01	3W39	7118	PYSDQRLRPRRTVF	-4.4836	-5.5189
HLA-A11:01	4UQ2	7118	PYSDQRLRPRRTVF	-10.0067	-10.1201
HLA-A11:01	4UQ2	7118	PYSDQRLRPRRTVF	-9.03915	-10.0745
HLA-A24:02	5HGA	7118	PYSDQRLRPRRTVF	-6.56204	-6.67544
HLA-A24:02	5HGA	7118	PYSDQRLRPRRTVF	-5.42271	-6.45801
HLA-B44:05	3DX8	7118	PYSDQRLRPRRTVF	-7.85648	-8.89178
HLA-B44:05	3DX8	7118	PYSDQRLRPRRTVF	-5.3978	-5.5112
HLA-A02:01	6TDR	7118	PYSDQRLRPRRTVF	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of TMEM106B-ABCB5

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	10	19	QRLRPRRTV	AAGAAGAACAGTTTTTACTGCAATTGC
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	10	20	QRLRPRRTVF	AAGAAGAACAGTTTTTACTGCAATTGCATA
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	11	20	RLRPRRTVF	AAGAACAGTTTTTACTGCAATTGCATA
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	3	14	ALIPYSDQRLR	TAGTGATCAGAGATTAAGGCCAAGAAGAACAGT
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	9	18	DQRLRPRRT	GCCAAGAAGAACAGTTTTTACTGCAAT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	0	15	QLVALIPYSDQRLRP	GATTCCATATAGTGATCAGAGATTAAGGCCAAGAAGAACAGTTTT
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	1	16	LVALIPYSDQRLRPR	TCCATATAGTGATCAGAGATTAAGGCCAAGAAGAACAGTTTTTAC
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	2	17	VALIPYSDQRLRPRR	ATATAGTGATCAGAGATTAAGGCCAAGAAGAACAGTTTTTACTGC
TMEM106B-ABCB5	chr7	12258147	chr7	20778606	3	18	ALIPYSDQRLRPRRT	TAGTGATCAGAGATTAAGGCCAAGAAGAACAGTTTTTACTGCAAT

Top

Information of the samples that have these potential fusion neoantigens of TMEM106B-ABCB5

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	TMEM106B-ABCB5	chr7	12258147	ENST00000396667	chr7	20778606	ENST00000258738	TCGA-A2-A0CL-01A

Top

Potential target of CAR-T therapy development for TMEM106B-ABCB5

Predicted 3D structure. We used RoseTTAFold.

494_TMEM106B-ABCB5_f3c0d_pred.pdb

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000258738

693_713

813.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000258738

737_757

813.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000258738

827_847

813.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000258738

917_937

813.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000258738

954_974

813.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000404938

954_974

1258.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

110_130

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

181_201

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

203_223

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

294_314

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

322_342

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

49_69

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

693_713

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

737_757

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

827_847

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

917_937

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000406935

954_974

127.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

110_130

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

181_201

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

203_223

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

294_314

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

322_342

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

49_69

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

693_713

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

737_757

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

827_847

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

917_937

132.0

Transmembrane

Helical

Tgene

ABCB5

chr7:12258147

chr7:20778606

ENST00000443026

954_974

132.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene	Hchr	Hbp	Henst	Tgene	Tchr	Tbp	Tenst	DeepLoc result
TMEM106B	chr7	12258147	ENST00000396667	ABCB5	chr7	20778606	ENST00000258738
TMEM106B	chr7	12258147	ENST00000396667	ABCB5	chr7	20778606	ENST00000404938
TMEM106B	chr7	12258147	ENST00000396668	ABCB5	chr7	20778606	ENST00000258738
TMEM106B	chr7	12258147	ENST00000396668	ABCB5	chr7	20778606	ENST00000404938

Top

Related Drugs to TMEM106B-ABCB5

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to TMEM106B-ABCB5

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)